JeffreyÂ N Weitzel

List of Publications by Year
in descending order

137	13,396	34105	24258
papers	citations	52 h-index	110 g-index

143	143	143	15232
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity. Genetics in Medicine, 2022, 24, 673-680.	2.4	4
2	Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer. Salud Publica De Mexico, 2022, 64, 41-48.	0.4	0
3	Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1621-1629.	2.5	2
4	Breast cancer associated pathogenic variants among women 61â€¯years and older with triple negative breast cancer. Journal of Geriatric Oncology, 2021, 12, 749-751.	1.0	8
5	Cancer health disparities in racial/ethnic minorities in the United States. British Journal of Cancer, 2021, 124, 315-332.	6.4	447
6	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	12.8	19
7	A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 2021, 384, 440-451.	27.0	414
8	Incidental detection of acquired variants in germline genetic and genomic testing: a points to consider statement of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1179-1184.	2.4	13
9	Germline mutations and age at onset of lung adenocarcinoma. Cancer, 2021, 127, 2801-2806.	4.1	14
10	Multigene assessment of genetic risk for women for two or more breast cancers. Breast Cancer Research and Treatment, 2021, 188, 759-768.	2.5	4
11	Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick Model. JCO Precision Oncology, 2021, 5, 1073-1081.	3.0	9
12	Development and Pilot Implementation of the Genomic Risk Assessment for Cancer Implementation and Sustainment (GRACIAS) Intervention in Mexico. JCO Global Oncology, 2021, 7, 992-1002.	1.8	6
13	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. Journal of Clinical Oncology, 2021, 39, 3430-3440.	1.6	21
14	Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. Journal of Clinical Oncology, 2021, 39, 2564-2573.	1.6	47
15	Genetic epidemiology of BRCA1- and BRCA2-associated cancer across Latin America. Npj Breast Cancer, 2021, 7, 107.	5.2	13
16	Weight Gain and the Risk of Ovarian Cancer in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2038-2043.	2.5	6
17	Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 77-102.	4.9	498
18	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. Journal of Clinical Oncology, 2021, 39, 3918-3926.	1.6	22

#	Article	IF	Citations
19	Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set. JAMA Oncology, 2021, 7, 1800.	7.1	55
20	Evaluation of TP53 Variants Detected on Peripheral Blood or Saliva Testing: Discerning Germline From Somatic TP53 Variants. JCO Precision Oncology, 2021, 5, 1677-1686.	3.0	7
21	Influence of Germline BRCA Genotype on the Survival of Patients with Triple-Negative Breast Cancer. Cancer Research Communications, 2021, 1, 140-147.	1.7	1
22	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
23	Older breast cancer survivors may harbor hereditary cancer predisposition pathogenic variants and are at risk for clonal hematopoiesis. Journal of Geriatric Oncology, 2020, 11, 316-319.	1.0	8
24	A Polygenic Risk Score for Breast Cancer in US Latinas and Latin American Women. Journal of the National Cancer Institute, 2020, 112, 590-598.	6.3	53
25	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
26	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
27	Circulating tumor DNA as an early cancer detection tool. , 2020, 207, 107458.		123
28	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	2.4	82
29	A Rare TP53 Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. Cancer Research, 2020, 80, 3732-3744.	0.9	32
30	Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes. JAMA Network Open, 2020, 3, e208501.	5.9	79
31	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. Npj Breast Cancer, 2020, 6, 44.	5.2	5
32	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. JCO Precision Oncology, 2020, 4, 916-925.	3.0	9
33	Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients. BMC Cancer, 2020, 20, 1053.	2.6	10
34	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
35	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. Journal of the National Cancer Institute, 2020, 112, 1213-1221.	6.3	51
36	Li-Fraumeni Exploration Consortium Data Coordinating Center: Building an Interactive Web-Based Resource for Collaborative International Cancer Epidemiology Research for a Rare Condition. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 927-935.	2.5	7

#	Article	IF	Citations
37	Development and Validation of a Clinical Polygenic Risk Score to Predict Breast Cancer Risk. JCO Precision Oncology, 2020, 4, 585-592.	3.0	41
38	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
39	Genetic cancer predisposition syndromes among older adults. Journal of Geriatric Oncology, 2020, 11, 1054-1060.	1.0	4
40	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	4.9	314
41	Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Science Translational Medicine, 2019, 11, .	12.4	197
42	Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2517-2521.	2.0	19
43	Genetics of gastric cancer: what do we know about the genetic risks?. Translational Gastroenterology and Hepatology, 2019, 4, 55-55.	3.0	30
44	Li-Fraumeni syndrome: not a straightforward diagnosis anymoreâ€"the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Research, 2019, 21, 107.	5.0	51
45	Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCAâ€negative Hispanics with breast cancer. Cancer, 2019, 125, 2829-2836.	4.1	43
46	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	6.4	19
47	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	2.5	26
48	The Burden of Breast Cancer Predisposition Variants Across The Age Spectrum Among 10 000 Patients. Journal of the American Geriatrics Society, 2019, 67, 884-888.	2.6	11
49	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
50	Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. Cancer Genetics, 2019, 235-236, 31-38.	0.4	23
51	International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. British Journal of Cancer, 2019, 121, 15-21.	6.4	101
52	Identification of novel common breast cancer risk variants at the 6q25 locusÂamong Latinas. Breast Cancer Research, 2019, 21, 3.	5.0	32
53	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	6.3	30
54	Experience Gained from the Development and Execution of a Multidisciplinary Multi-syndrome Hereditary Colon Cancer Family Conference. Journal of Cancer Education, 2019, 34, 1204-1212.	1.3	3

#	Article	IF	Citations
55	The effects of genomic germline variant reclassification on clinical cancer care. Oncotarget, 2019, 10, 417-423.	1.8	40
56	Prospective Study of Cancer Genetic Variants: Variation in Rate of Reclassification by Ancestry. Journal of the National Cancer Institute, 2018, 110, 1059-1066.	6.3	48
57	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
58	The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Familial Cancer, 2018, 17, 235-245.	1.9	29
59	Somatic TP53 variants frequently confound germ-line testing results. Genetics in Medicine, 2018, 20, 809-816.	2.4	91
60	Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Journal of Clinical Oncology, 2018, 36, 3459-3465.	1.6	79
61	Age at first full-term birth and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2018, 171, 421-426.	2.5	10
62	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
63	Spectrum of mismatch repair gene mutations and clinical presentation of Hispanic individuals with Lynch syndrome. Cancer Genetics, 2017, 212-213, 1-7.	0.4	4
64	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 9-20.	4.9	408
65	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. Npj Breast Cancer, 2017, 3, 22.	5.2	108
66	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
67	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
68	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging. JAMA Oncology, 2017, 3, 1634.	7.1	148
69	Genetic Gastric Cancer Susceptibility in the International Clinical Cancer Genomics Community Research Network. Cancer Genetics, 2017, 216-217, 111-119.	0.4	42
70	Bilateral Oophorectomy and Breast Cancer Risk inBRCA1andBRCA2Mutation Carriers. Journal of the National Cancer Institute, 2017, 109, .	6.3	160
71	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS ONE, 2016, 11, e0158801.	2.5	10
72	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31

#	Article	IF	Citations
73	Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution. Journal of Community Genetics, 2016, 7, 177-183.	1.2	39
74	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	5.0	88
75	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer Discovery, 2016, 6, 1267-1275.	9.4	41
76	Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2. Breast Cancer Research and Treatment, 2016, 160, 121-129.	2.5	11
77	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Research, 2016, 18, 112.	5.0	42
78	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
79	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
80	Prevalence of Hispanic BRCA1 and BRCA2 mutations among hereditary breast and ovarian cancer patients from Brazil reveals differences among Latin American populations. Cancer Genetics, 2016, 209, 417-422.	0.4	33
81	Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer. JAMA Oncology, 2016, 2, 723.	7.1	10
82	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
83	Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 268-276.	2.0	36
84	Comprehensive spectrum ofBRCA1andBRCA2deleterious mutations in breast cancer in Asian countries. Journal of Medical Genetics, 2016, 53, 15-23.	3.2	82
85	PMS2 monoallelic mutation carriers: the known unknown. Genetics in Medicine, 2016, 18, 13-19.	2.4	51
86	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
87	Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Frontiers in Oncology, 2015, 5, 208.	2.8	109
88	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
89	Next-Generation Testing for Cancer Risk: Perceptions, Experiences, and Needs Among Early Adopters in Community Healthcare Settings. Genetic Testing and Molecular Biomarkers, 2015, 19, 657-665.	0.7	42
90	The Genetics of Breast Cancer. Surgical Oncology Clinics of North America, 2015, 24, 705-732.	1.5	5

#	Article	IF	Citations
91	Factors influencing ovulation and the risk of ovarian cancer in <scp>BRCA1</scp> and <scp>BRCA2</scp> mutation carriers. International Journal of Cancer, 2015, 137, 1136-1146.	5.1	56
92	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	2.5	22
93	Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer, 2015, 121, 372-378.	4.1	78
94	Appreciating the broad clinical features of SMAD4 mutation carriers: a multicenter chart review. Genetics in Medicine, 2014, 16, 588-593.	2.4	62
95	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
96	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
97	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	27.0	745
98	Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from MedellÃn, Colombia. Hereditary Cancer in Clinical Practice, 2014, 12, 11.	1.5	42
99	Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome. Molecular Diagnosis and Therapy, 2013, 17, 31-47.	3.8	82
100	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
101	Identification of a BRCA2-Specific Modifier Locus at 6p24 Related to Breast Cancer Risk. PLoS Genetics, 2013, 9, e1003173.	3.5	105
102	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	3.5	244
103	Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. Journal of Clinical Oncology, 2013, 31, 210-216.	1.6	140
104	Impact of Web-Based Case Conferencing on Cancer Genetics Training Outcomes for Community-Based Clinicians. Journal of Cancer Education, 2012, 27, 217-225.	1.3	21
105	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 2012, 133, 1125-1130.	2.5	144
106	BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecologic Oncology, 2012, 124, 236-243.	1.4	60
107	Genetics, genomics, and cancer risk assessment. Ca-A Cancer Journal for Clinicians, 2011, 61, 327-359.	329.8	172
108	Pathological characteristics of BRCA-associated breast cancers in Hispanics. Breast Cancer Research and Treatment, 2011, 130, 281-289.	2.5	17

#	Article	IF	Citations
109	Personalized cancer genetics training for personalized medicine: Improving community-based healthcare through a genetically literate workforce. Genetics in Medicine, 2011, 13, 832-840.	2.4	42
110	Extending Comprehensive Cancer Center Expertise in Clinical Cancer Genetics and Genomics to Diverse Communities: The Power of Partnership. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 615-624.	4.9	45
111	Evolving perspectives on genetic discrimination in health insurance among health care providers. Familial Cancer, 2010, 9, 253-260.	1.9	21
112	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptorâ€“negative breast cancer in the general population. Nature Genetics, 2010, 42, 885-892.	21.4	309
113	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. Cancer Research, 2010, 70, 9742-9754.	0.9	169
114	Association of Risk-Reducing Surgery in <emph type="ital">BRCA1</emph> or <emph type="ital">BRCA2</emph> Mutation Carriers With Cancer Risk and Mortality. JAMA - Journal of the American Medical Association, 2010, 304, 967.	7.4	1,241
115	Reply to J. Tinat et al. Journal of Clinical Oncology, 2009, 27, e110-e110.	1.6	0
116	Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations. Journal of Clinical Oncology, 2009, 27, 1250-1256.	1.6	532
117	Absence of the BRCA1 del (exons 9â€“12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Research and Treatment, 2009, 117, 679-681.	2.5	19
118	Socialâ€cognitive aspects of underserved Latinas preparing to undergo genetic cancer risk assessment for hereditary breast and ovarian cancer. Psycho-Oncology, 2008, 17, 774-782.	2.3	45
119	Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. American Journal of Human Genetics, 2008, 82, 937-948.	6.2	257
120	Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer. JAMA - Journal of the American Medical Association, 2007, 297, 2587.	7.4	164
121	Reduced Mammographic Density with Use of a Gonadotropin-Releasing Hormone Agonistâ€“Based Chemoprevention Regimen in BRCA1 Carriers. Clinical Cancer Research, 2007, 13, 654-658.	7.0	36
122	Evidence for Common Ancestral Origin of a Recurring BRCA1 Genomic Rearrangement Identified in High-Risk Hispanic Families. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 1615-1620.	2.5	92
123	Validity of Models for Predicting BRCA1 and BRCA2 Mutations. Annals of Internal Medicine, 2007, 147, 441.	3.9	106
124	Beliefs and interest in cancer risk in an underserved Latino cohort. Preventive Medicine, 2007, 44, 241-245.	3.4	32
125	RAD51 135Gâ†’C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. American Journal of Human Genetics, 2007, 81, 1186-1200.	6.2	217
126	If We Build Itâ€‰â€¦Will They Come? â€“ Establishing a Cancer Genetics Services Clinic for an Underserved Predominantly Latina Cohort. Journal of Genetic Counseling, 2006, 15, 505-514.	1.6	59

#	Article	IF	Citations
127	Outcomes from intensive training in genetic cancer risk counseling for clinicians. Genetics in Medicine, 2005, 7, 40-47.	2.4	31
128	Linkage of a Pedigree Drawing Program and Database to a Program for Determining BRCA Mutation Carrier Probability. Familial Cancer, 2005, 4, 313-316.	1.9	6
129	A Comparison of Bilateral Breast Cancers in BRCA Carriers. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1534-1538.	2.5	44
130	Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1666-1671.	2.5	157
131	Effect of Genetic Cancer Risk Assessment on Surgical Decisions at Breast Cancer Diagnosis. Archives of Surgery (Chicago, Ill: 1920), 2003, 138, 1323.	1.4	155
132	Restriction endonuclease fingerprinting enhanced conformation sensitive gel electrophoresis (REF-CSGE) in the analysis ofBRCA1 exon 11 mutations in a high-risk breast cancer cohort. Human Mutation, 2002, 19, 656-663.	2.5	7
133	Genetic cancer risk assessment. Cancer, 1999, 86, 2483-2492.	4.1	47
134	Genetic cancer risk assessment. Cancer, 1999, 86, 2483-2492.	4.1	23
135	The current social, political, and medical role of genetic testing in familial breast and ovarian carcinomas. Current Opinion in Obstetrics and Gynecology, 1999, 11, 65-70.	2.0	6
136	The crystal ball of genetic cancer risk assessment: Who wouldn't want to know their future?. Annals of Surgical Oncology, 1998, 5, 567-568.	1.5	1
137	Crossâ€sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment. Journal of Genetic Counseling, 0, , .	1.6	0